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Both p53 and ATM are checkpoint regulators with roles in genetic stabilization and cancer susceptibility.
ATM appears to function in the same DNA damage checkpoint pathway as p53. However, ATM’s role in
p53-dependent apoptosis and tumor suppression in response to cell cycle dysregulation is unknown. In this
study, we tested the role of murine ataxia telangiectasia protein (Atm) in a transgenic mouse brain tumor
model in which p53-mediated apoptosis results in tumor suppression. These p53-mediated activities are
induced by tissue-specific inactivation of pRb family proteins by a truncated simian virus 40 large T antigen
in brain epithelium. We show that p53-dependent apoptosis, transactivation, and tumor suppression are
unaffected by Atm deficiency, suggesting that signaling in the DNA damage pathway is distinct from that in the
oncogene-induced pathway. In addition, we show that Atm deficiency has no overall effect on tumor growth and
progression in this model.
The p53 tumor suppressor and ATM (mutated in human
ataxia telangiectasia [AT] disease; Atm in mice) are both can-
cer susceptibility genes with roles in checkpoint regulation (9,
22, 23). Each is associated with distinct human genetic disor-
ders in which patients are prone to cancer. Patients with Li-
Fraumeni syndrome carry a mutant p53 allele and develop a
variety of cancers, including mammary adenocarcinomas, sar-
comas, brain tumors, and leukemia (21, 33). The p53 gene is
also mutated in about 50% of sporadic human cancers (6, 11).
AT is an autosomal recessive disease characterized by cerebel-
lar degeneration, oculocutaneous telangiectasia, retarded
growth, infertility, sensitivity to ionizing radiation (IR), and a
high incidence of cancers, most commonly lymphoid malignan-
cies (17, 30). The early deaths of most homozygous AT pa-
tients preclude an accurate assessment of the full tumor spec-
trum and the frequency of ATM deficiency in humans. Thus,
human disease progression alone cannot predict whether p53
and ATM share tumor suppressor pathways.
p53 is involved in the cellular responses to a variety of stress
signals, the best characterized of which is DNA damage (7, 32).
In response to a given signal, p53 can induce cell cycle arrest or
apoptosis, and these functions appear to be involved in its
ability to suppress tumorigenesis. p53 deficiency can promote
tumor growth by a reduction in the level of apoptosis, an event
for which there would be substantial selection (12, 25, 34).
Alternatively (or in addition), since p53-deficient cells are
prone to genomic instability (20, 44), the loss of p53 responses
may promote tumor progression through the genetic alteration
of other cancer genes (8, 15, 16).
ATM is also involved in checkpoint regulation. It belongs to
the phosphatidylinositol-39 kinase superfamily, a family of sig-
nal transduction proteins with homology in their carboxyl ki-
nase domains (29). In response to DNA damage, this 350-kDa
protein kinase appears to be required for checkpoints in G1, S,
and G2 phases (22, 23). Cultured cells derived from AT pa-
tients or from Atm-deficient mice are highly abnormal. These
cells grow slowly and exhibit senescence prematurely (2, 17,
41). They demonstrate high rates of spontaneous apoptosis
and a hypersensitivity to IR (22). Genome instability charac-
terized by frequent chromosomal translocations and telomere
defects is also commonly observed in AT cells (31, 35). Atm-
deficient mice display many of the human AT phenotypes, such
as retarded growth, infertility, sensitivity to IR, neurological
dysfunction (although mild), and tumor proneness (2, 5, 40).
Evidence that ATM and p53 could act in the same pathway
comes from studies of cell lines derived from AT patients and
of knockout mice. Induction of p53 and G1 arrest in response
to DNA damage is impaired in AT cell lines (14) and in mouse
Atm2/2 embryonic stem cells (41), embryo fibroblasts, and
thymus cells (1, 2), indicating that ATM acts upstream of p53
in response to DNA damage. Both p532/2 (4, 13) and Atm2/2
(2, 5, 40) mice develop thymic lymphoma, also suggesting the
possibility of a common thymocyte tumor suppression path-
way.
In addition to DNA damage, p53 is activated by many other
signals, such as hypoxia, low ribonucleoside triphosphate lev-
els, and oncogene-induced aberrant proliferation (7, 18). Dys-
regulated cell cycle activity has been shown to signal p53-
dependent apoptosis and tumor suppression in vivo (12, 24, 25,
34). It is not clear whether these different stress signals are
transduced to p53 via common or distinct upstream molecular
pathways.
Based on the established link between Atm and p53 in re-
sponse to DNA damage, we addressed the role of Atm in
p53-dependent apoptosis and tumor suppression when in-
duced by aberrant cell cycle activities by using the transgenic
TgT121 brain tumor model. T121 is a truncated simian virus 40
large T antigen that binds and inactivates pRb and the related
proteins p107 and p130 (27). Tissue-specific expression of this
oncoprotein in brain choroid plexus epithelium (CP) induces
the aberrant proliferation of these normally quiescent cells,
and a measurable p53-dependent apoptosis pathway that sup-
presses tumor growth is activated (Fig. 1A). Inactivation of p53
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causes an 85% reduction in CP apoptosis and accelerates tu-
mor growth sevenfold (34). This model provides a quantitative
test for p53 tumor suppression activities in vivo. In this study
we assessed the impact of Atm deficiency on p53-mediated
apoptosis and tumor suppression in these mice.
MATERIALS AND METHODS
Mice. TgT121 mice carry a transgene that expresses T121 specifically in CP
under the control of lymphotropic papovavirus transcriptional signals (28). T121
consists of the simian virus 40 T-antigen N-terminal 121 amino acids with 11
C-terminal missense residues (27). The Atm2/2 mice carry a truncation mutation
at nucleotide 5790 caused by a PGKneo gene insertion (2). TgT121 (C57BL/6 3
DBA2) mice were bred with Atm1/2 mice (C57BL/6 3 129sv) to generate
(TgT121 3 Atm1/2) F1 mice. F1 mice were further intercrossed to generate
TgT121 Atm2/2 mice (C57BL/6 3 DBA2 3 129sv). TgT121 and Atm2/2 geno-
types were determined by PCR analysis of tail DNA. TgT121 screening has been
described previously (28). PCR primers were designed for genotyping Atm2/2
mice. Primer pairs Atm-F (59-GAC TTC TGT CAG ATG TTG CTG CC-39) and
Atm-B (59-CGA ATT TGC AGG AGT TGC TGA G-39) were used to identify
the wild-type Atm allele, and Atm-F and Atm-Neo (59-GGG TGG GAT TAG
ATA AAT GCC TG-39) were used to identify the knockout allele by performing
35 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min. The Atm-F–
Atm-B pair generates a 162-bp PCR product, and the Atm-F–Atm-Neo pair
generates a 441-bp PCR product.
Western blotting. Western blotting analysis was carried out as previously
described (39). Two hundred micrograms of protein from total cell lysates of
fresh tissues was resolved by sodium dodecyl sulfate–5% polyacrylamide gel
electrophoresis (cross-linking ratio, 29:1). Two independent anti-human ATM
antibodies, 2C6 (3) and 473 (kindly provided by Eva Lee and Michael Kastan,
respectively), were used separately to detect Atm protein expression in TgT121
CP. The results were the same with both reagents. The enhanced chemilumi-
nescence system (Amersham) was used according to the manufacturer’s instruc-
tions.
Histology, S-phase, and apoptosis assays. Brain tissues were fixed in 10%
formalin, embedded in paraffin, and sectioned as previously described (34). To
examine tumor size, 6-mm sections were taken from 10 successive layers at
100-mm intervals. For histology assays, sections were stained with hematoxylin
and eosin as previously described (34). Bromodeoxyuridine (BrdU) labeling and
immunostaining as well as the terminal deoxynucleotidyltransferase-mediated
dUTP-biotin nick end labeling (TUNEL) apoptosis assay were completed as
previously described (34, 43). Quantification was made by averaging the percent-
age of positive cells in 10 random fields at a magnification of 3400.
In situ RNA hybridization. Sections (6 mm) were hybridized with p21 or Bax
antisense probes as previously described (26, 43). Probes were radiolabeled with
a-35S-UTP and used at a concentration of 5 3 104 cpm ml21. Autoradiography
was conducted at 4°C for 3 days for the p21 probe and at 4°C for 3 weeks for the
Bax probe. Signal densities were quantified with NIH Image 1.58. The threshold
was set by using the sense probe signals as the background. Means were deter-
mined from 10 random areas of CP for each sample.
RESULTS
p53-dependent apoptosis does not require Atm. A genetic
approach has been taken to determine the pathway by which
p53-dependent apoptosis and tumor suppression proceed in
TgT121 mice. For example, by assessing the rates of apoptosis
and tumor growth in a background with specific deficiencies,
we previously determined that E2F1 is upstream (26) and Bax
is downstream (43) of p53 in this system. The possibility that
Atm could be active in TgT121 CP is demonstrated by the
detection of Atm in this tissue by Western blotting analysis
(Fig. 1B). A spleen extract from an Atm2/2 mouse served as a
negative control and showed no specific proteins the size of
Atm (Fig. 1B, lane 1). In contrast, spleen and thymus tissues
from a wild-type mouse (lanes 2 and 3) and CP from a TgT121
mouse (lane 4) contained a 350-kDa Atm-specific doublet de-
tectable with two independent ATM-specific antibodies (the
results presented in Fig. 1B were obtained with the 2C6 mono-
clonal antibody).
To examine whether Atm deficiency has a role in p53 tumor
suppression activities, we generated TgT121 Atm
2/2 mice
through a series of crosses by using TgT121 (28) and Atm
1/2
(2) mice. We first assessed the effect of Atm deficiency on
T121-induced p53-dependent apoptosis by using the in situ
TUNEL assay (Fig. 2A). The CP apoptotic index (AI) was
determined for brain sections from TgT121 Atm
2/2 mice, which
were compared to TgT121 Atm
1/1 littermates. Previously,
TgT121 CP cells were shown to have an average AI of 7.3%,
85% of which requires functional p53 (34). In the present
study, the CP AI of TgT121 Atm
1/1 littermate controls was
similar, averaging 6.69% 6 0.17% (Fig. 2B). The CP of control
Atm2/2 mice appeared to be normal, with no apoptotic activity
(Table 1). The AI in TgT121 Atm
2/2 CP was similar to that of
TgT121 Atm
1/1 mice (7.17% 6 0.99%) (Fig. 2; Table 1). This
is in stark contrast to the dramatic decrease in AI caused by
p53 deficiency (Table 1; Fig. 2C) (34). Thus, in this system,
p53-dependent apoptosis in response to abnormal prolifera-
tion does not require Atm.
Intact p53 transactivation activity in the absence of Atm. To
further assess the impact of Atm deficiency on p53 function, we
examined p53 transactivation activity in TgT121 Atm
2/2 CP.
We previously showed that T121 expression in the CP induces
the p53-regulated genes bax (43), p21 (26), and mdm2 (26) in
a p53-dependent manner. To assess the p53 transactivation
activity in the absence of Atm, bax and p21 transcript levels
were measured in TgT121 Atm
2/2 and TgT121 Atm
1/1 brain
sections by in situ RNA hybridization (Fig. 3). Samples from
young mice (5 to 7 weeks) were analyzed to avoid the influence
of spontaneous genetic changes during tumor progression.
Quantitative analysis indicated that p53-dependent p21 and
FIG. 1. Is Atm required for p53-dependent apoptosis and tumor suppression
in the TgT121 brain tumor model? (A) Transgenic expression of T121 in CP
inactivates pRb family proteins (pRb-f) (including pRb, p107, and p130), result-
ing in abnormal proliferation and tumorigenesis. As a result, p53 is activated,
causing apoptosis and attenuation of tumor growth (34). (B) Atm is expressed in
T121 CP. Western immunoblotting was performed on tissue extracts by using a
monoclonal antibody specific for ATM, 2C6. Lane 1, Atm2/2 spleen (negative
control); lanes 2 and 3, thymus and spleen tissues, respectively, of a wild-type
mouse (positive control); lane 4, TgT121 CP. Two resolvable Atm-specific bands
the size of mouse Atm are detectable in lanes 2 through 4 and are absent from
the negative control. The position of a 175-kDa molecular mass marker is shown
on the right.
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bax RNA levels in the CP remain unchanged in the absence of
Atm (Fig. 3A through D). The levels of p21 and bax transcripts
in TgT121 Atm
2/2 CP were 99% 6 4.8% and 105% 6 8%,
respectively, of those of TgT121 Atm
1/1 littermates (Fig. 3G).
All p21 expression in these cells was dependent on p53 activity
(Fig. 3E), as was much of the bax expression, as previously
observed (Fig. 3F). In this system, Bax is involved in p53-
dependent apoptosis (43), while p21 is not (our unpublished
FIG. 2. p53-mediated apoptosis does not require Atm. (A) Apoptotic cells in CP (arrows) were detected by the TUNEL assay. No qualitative changes were detected
between TgT121 and TgT121 Atm2/2 CP tumor cells. (B) Quantitative apoptotic indices in TgT121 and TgT121 Atm2/2 CP. The percentages of apoptotic cells were
determined for TgT121 (open bars) and TgT121 Atm2/2 (solid bars) littermates at different ages. Each bar in the left panel represents the averaged counts from 10 fields
of one sample from one mouse at the specified age. The averages of all four mice are shown at the right. The error bars represent the standard deviations among
microscopic fields (left) or among mice (right). (C) Impact of Atm deficiency on apoptosis compared with impact of p53 and E2F1 deficiency. Atm deficiency has no
effect on apoptosis in TgT121 CP cells, while p53 and E2F1 account for 85 and 80% of the apoptosis, respectively (26, 34).
TABLE 1. Atm impact on tumor growth
Genotype % of apoptotic cellsa % of S-phase cellsa Type of CPneoplastic growth




Atm2/2 0c 0c None 20.2 6 3.9 (6) Thymoma
TgT121 100 100 Slow 31.0 6 1.6 (16) CP tumor
TgT121 Atm
1/2 98c 120c Slow 37.2 6 4.21 (6) CP tumor
TgT121 Atm
2/2 107 6 15 103 6 33 Slow 22.7 6 1.8 (15) Thymoma
TgT121 p53
2/2d 14 6 10 109c Rapid 4 6 0.2 (4) CP tumor
a Relative to the level in TgT121 CP.
b Values in parentheses are numbers of mice tested. Mean survival times of TgT121 and TgT121 Atm1/2 mice are not significantly different (P 5 0.1026 in an unpaired
two-tailed t test). The difference may reflect background strain differences (TgT121 mice are C57BL/6 3 DBA2; TgT121 Atm1/2 mice are C57BL/6 3 DBA2 3 129sv).
c From a single sample.
d Data from reference 34; TgT121 p532/2 mice are of a C57BL/6 3 DBA2 3 129sv background.
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results). Thus, Atm is dispensable for T121-induced p53 trans-
activation functions that are apoptosis dependent as well as
independent.
Effects of Atm deficiency on tumor cell proliferation and
overall tumor growth. Although the above results show that
Atm is not required for p53-dependent apoptosis or transac-
tivation, Atm could affect CP tumor growth by other mecha-
nisms. For example, Atm deficiency could diminish tumor
growth since Atm2/2 fibroblasts exhibit poor growth and a
reduced life span in culture (2, 41). Alternatively, Atm inacti-
vation could accelerate tumor growth through genetic instabil-
ity, as proposed for Atm deficiency-induced lymphoma and
leukemia (35).
To determine whether Atm deficiency has an impact on CP
tumor cell proliferation, we measured S-phase indices by in
vivo BrdU incorporation (Fig. 4A). Mice were analyzed at
FIG. 3. Atm deficiency does not affect p53 transactivation function in CP. Representative in situ RNA hybridization signals are shown for p21 (A, C, and E) and
bax (B, D, and F) expression. p21 RNA is readily detectable in TgT121 (A) as well as in TgT121 Atm2/2 (C) CP. bax RNA levels are also equally expressed in TgT121
(B) and TgT121 Atm2/2 (D) cells. bax and p21 expression in TgT121 CP are both p53 dependent, as seen in TgT121 p532/2 cells (E and F). (G) Quantitative comparisons
of RNA levels; signals in TgT121 are designated as 100%. The signal detected in CP by using a bax or p21 sense probe was at about the background level, ensuring the
specificity of the assay. Ten fields of each sample were analyzed. Standard errors in each field are less than 10% of the relative mean value.
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various times during early tumor growth (5 to 14 weeks) to
circumvent selective changes during tumor progression. No
difference was detected in the percentage of S-phase CP in
TgT121 Atm
2/2 and TgT121 Atm
1/1 littermates (Table 1).
TgT121 Atm
2/2 CP averaged 10.6% 6 3.4% of cells in S phase,
while TgT121 Atm
1/1 CP averaged 10.3% 6 2.8% of cells in S
phase (Fig. 4B). Therefore, unlike fibroblast growth in culture,
Atm deficiency had no measurable impact on CP tumor cell
proliferation in vivo.
Although the apoptotic and proliferative indices of TgT121
CP were not affected by Atm inactivation, an effect on tumor
morphology and progression was possible. To determine the
overall impact of Atm deficiency on tumor growth, the survival
times, tumor sizes, and morphologies of TgT121 Atm
2/2 mice
were compared to those of TgT121 Atm
1/1 littermates. Control
TgT121 and Atm-deficient mice developed different tumor
types and had different average survival times. TgT121 mice
died of brain tumors with an average survival time of 31 weeks,
whereas Atm-deficient mice died of thymoma with an average
survival time of 20 weeks (Table 1). Like Atm2/2 mice, all
TgT121 Atm
2/2 mice developed thymic lymphoma (average
survival time of 23 weeks [Table 1]). The difference between
thymoma development in Atm2/2 mice and that in TgT121
Atm2/2 mice is not statistically significant (P 5 0.5115 in an
unpaired two-tailed t test) and could be due to background
strain differences (C57BL/6 3 129sv versus C57BL/6 3
DBA2 3 129sv) or due to T121 expression in thymocytes (28).
Although TgT121 Atm
2/2 mice succumbed to thymic lym-
phoma prior to the terminal age anticipated for mice with
brain tumors, their lengthy survival indicates that Atm defi-
FIG. 4. Effects of Atm deficiency on tumor cell proliferation. TgT121 and TgT121 Atm2/2 CP were stained for BrdU incorporation to measure proliferation rates.
(A) Representative views of CP from TgT121 and TgT121 Atm2/2 7-week-old littermates stained for BrdU (red), with nuclei counterstained by hematoxylin (blue). No
BrdU-staining cells are present in the surrounding brain parenchyma (BP). (B) Percentage of S-phase cells in TgT121 (open bars) and TgT121 Atm2/2 (solid bars) CP.
Left, percentage of proliferating cells in paired littermates (each bar represents brain sections from one mouse; error bars represent the standard deviations among
sets of 10 microscopic fields); right, averaged percentage of S-phase cells in these age-matched groups shown at the left (error bars represent standard deviations among
individual mice).
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ciency did not substantially accelerate the growth of T121-in-
duced brain tumors. CP tumors present in TgT121 Atm
2/2 mice
at the time of autopsy were comparable in size and morphology
to those in TgT121 mice of similar ages (data not shown).
Furthermore, assessment of tumor sizes at 4 to 20 weeks
showed no significant differences between TgT121 Atm
1/1 and
TgT121 Atm
2/2 littermates (Fig. 5). The CP of Atm2/2 mice
was morphologically normal. These results are consistent with
the observation that both apoptosis and proliferation were
unaffected by Atm deficiency. In sharp contrast, TgT121 p53
2/2
mice develop large tumor masses within 4 weeks (Fig. 5E;
Table 1) (34). Analysis of TgT121 Atm
1/2 mice also showed
that Atm deficiency did not promote tumor progression. Tu-
mor growth in TgT121 p53
1/2 mice progresses from slow
growth to highly aggressive and angiogenic growth within 7
weeks, leading to the death of the mice by 12 weeks of age (Fig.
5D) (34). This occurs in all mice and correlates with a high
frequency of p53 loss of heterozygocity. In contrast, no such
acceleration was observed in TgT121 Atm
1/2 mice (Fig. 5H).
DISCUSSION
Atm and p53. In this study we explored the possibility that
Atm functions in a p53 apoptosis and tumor suppression path-
way that is induced via aberrant proliferation rather than DNA
damage. The molecular signals involved in p53 induction in
this case are largely unknown. One possibility is that aberrant
S-phase activity generates DNA damage-like signals, in which
case the pathways could be coincident. Here, we show that
Atm deficiency does not impair p53 activation by inappropriate
cell cycle activity in brain epithelium. The approach used in
this study to study Atm has been used in previous studies to
identify both upstream (26) and downstream (43) effectors in
this pathway. E2F1 deficiency causes an 80% inhibition of
p53-dependent apoptosis (Fig. 2C) as well as inhibition of p53
transactivation function, indicating that E2F1 lies upstream of
p53 (26). Therefore, inactivation of pRb proteins by T121 leads
to E2F1 activation, which then induces p53 function (26). In
contrast, this report shows that Atm is not required in this
pathway—p53-dependent apoptosis, transactivation, and tu-
mor suppression are fully active in the absence of Atm. To-
gether, these data indicate that different stress signals are
transduced to p53 via distinct pathways.
Comparison of these results with those of previous reports
addressing the role of ATM in p53-dependent activities largely
supports the idea that the distinction observed here is based on
the inducing signal rather than cell type or biological response
(i.e., apoptosis or growth arrest). So far, ATM has been impli-
cated only in DNA damage-induced p53 responses, including
the induction of both growth arrest and apoptosis. Atm is
required for DNA damage-induced p53 induction and G1 ar-
rest in human (23) and mouse (2) fibroblasts and in mouse
embryonic stem cells (41) and thymus tissue (1). It is also
required for IR-induced p53-dependent apoptosis of neurons
in the developing central nervous system, since the irradiation
of newborn mice induces widespread central nervous system
apoptosis, coincident with p53 induction. This apoptosis is
dramatically reduced in both p53-deficient and Atm-deficient
mice (10).
In the thymus, IR-induced p53-dependent apoptosis is not
Atm dependent in vivo (1, 10), although the p53-dependent
G1/S checkpoint does require Atm (1). Therefore, within a
given tissue, distinct p53-mediated biological effects are in-
duced by apparently distinct pathways upstream of p53 (1).
Two reports show a partial reduction in the IR-induced p53-
dependent apoptosis of Atm2/2 thymus cells (41) or thymo-
cytes (37). This contradiction could indicate differences in thy-
mocyte subpopulations or could result from in vitro versus in
vivo approaches. In the present study, we have examined in
vivo apoptotic responses to show that Atm is dispensable for
p53-mediated apoptosis and tumor suppression in brain epi-
thelium. We cannot exclude the possibility that Atm-related
factors fully compensate for the absence of Atm.
Whether Atm and p53 participate in the same tumor sup-
FIG. 5. Effects of Atm deficiency on CP tumor growth and progression. Sizes of the CP masses (arrows) are shown. TgT121 mice at 7 weeks (B) and 14 weeks (C)
are compared to TgT121 Atm2/2 littermates (F and G, respectively). Note that p53 deficiency greatly accelerated tumor growth as indicated by the mass size at 4 weeks
(E versus A). CP tumor progression to aggressive angiogenic states was observed in TgT121 p531/2 mice (D) but not in TgT121 Atm1/2 mice (H). These views represent
the largest mass present among step sections sampled from the full brain to ensure a fair comparison of tumor sizes.
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pression pathways in other cell types is not known. Although
both Atm- and p53-deficient mice develop thymic lymphomas
with high frequency, in Atm p53 double-null mice, tumor
growth is accelerated (37, 42), indicating that Atm and p53
cooperate in thymocyte tumor suppression, rather than fall
within a linear pathway. In addition, V(D)J recombination-
associated translocations are frequent in thymomas from Atm-
deficient mice (2) but not in thymomas from p53-deficient mice
(19). Therefore, in mouse thymocytes, where both Atm and
p53 are proven tumor suppressors, the pathways may be dis-
tinct.
Atm and tumor growth. In the present study Atm deficiency
did not affect CP tumor cell proliferation or tumor growth
despite the fact that the proliferation of Atm2/2 fibroblasts was
impaired and senescence occurred prematurely. This lack of
Atm effect on CP tumor cell proliferation could reflect cell-
type-specific differences. In Atm2/2 fibroblasts, proliferative
defects can be rescued by the inactivation of either p21 or p53
(36, 38, 42). CP tumor cells express p21 abundantly and possess
functional p53. However, pRb (a known target of cyclin-de-
pendent kinases inhibited by p21) is inactivated by T121 in CP
tumor cells, possibly masking any growth-inhibitory effects of
Atm deficiency. Finally, we considered the possibility that ge-
netic instability induced by Atm deficiency could result in mea-
surable effects on tumor progression. TgT121 p53
1/2 CP tu-
mors progress to highly aggressive states with frequent p53 loss
of heterozygocity (34) and widespread aneuploidy (our unpub-
lished results). No such accelerated progression was observed
in TgT121 Atm
1/2 mice.
In summary, our results suggest that distinct signal transduc-
tion pathways may induce p53, depending on the cellular in-
sults. While Atm appears to be involved in p53 activation by
DNA damage, it is not required for p53 activation by aberrant
cell cycle activity in brain epithelium. Furthermore, when these
tumors are initiated by the inactivation of the pRb family, Atm
deficiency has no further impact on tumor growth and progres-
sion.
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